trial · primary record
Belzutifan
Renal Cell Carcinoma
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 140 |
| Primary completion | 2031-10-26 |
| Primary endpoint | Safety Lead In Phase: Number of participants who experience one or more dose-limiting toxicities (DLTs) |
| Registry ID | NCT07049926 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:32:21.444Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07049926
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.